In a phase Ib trial, led by Naval Daver and Michael Andreeff at MD Anderson Cancer Center, researchers evaluated the combination of Venclexta (venetoclax) and idasanutlin in 56 patients with R/R AML who were unfit for chemotherapy. IDH1/2 and RUNX1 mutations were associated with higher composite complete remission rates of 50% and 45%, respectively, and were linked to therapy sensitivity.
A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.
